GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Research & Development

Achilles Therapeutics (STU:698) Research & Development : €50.40 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Achilles Therapeutics's Research & Development for the three months ended in Mar. 2024 was €9.33 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €50.40 Mil.

Achilles Therapeutics Research & Development Historical Data

The historical data trend for Achilles Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Research & Development Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
8.17 18.60 37.37 54.06 53.41

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.95 12.71 13.79 14.57 9.33

Achilles Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €50.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achilles Therapeutics  (STU:698) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Achilles Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Achilles Therapeutics (STU:698) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Research & Development
Comparable Companies
NERV INKT PVCT COEP PASG HOOK VTVT EFTR CGTX SLGL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ACHL:USA 698:Germany
Address
245 Hammersmith Road, London, GBR, W6 8PW
Website
https://www.achillestx.com
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines